Vázquez TGM

Language: Spanish
References: 4
Page: 195-200.
PDF size: 253.72 Kb.

ABSTRACT

The 5th edition of the World Health Organization Classification of Hematolymphoid Tumors (2022) was recently published, in which there are important changes in the classification of myelodysplastic neoplasms. These changes focus on reorganize the categories of myelodysplastic neoplasms emphasizing the histological features and genetic variables. It is recognized that the subgroups established better classify patients according to clinical behavior and prognosis. The new classification of WHO of 2022 allows to predict clinical and biological behavior of patients with diagnosis of myelodysplastic neoplasm, because it defines subgroups of the disease with higher risk of progression to leukemia.

REFERENCES

1. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, ApperleyJF, et al. The 5th edition of the World Health Organizationclassification of Haematolymphoid Tumours: Myeloid andhistiocytic/dendritic neoplasms. Leukemia 2022; 36 (7):1703-19. http://dx.doi.org/10.1038/s41375-022-01613-1

2. Tria FP IV, Ang DC, Fan G. Myelodysplastic syndrome:Diagnosis and screening. Diagnostics 2022; 12 (7): 1581.https://doi.org/10.3390/diagnostics12071581.

3. Sekeres MA, Taylor J. Diagnosis and treatment of myelodysplasticsyndromes: A review. JAMA 2022; 328 (9): 872-880.doi: 10.1001/jama.2022.14578.

4. Zhang Y, Wu J, Qin T, et al. Comparison of the revised4th (2016) and 5th (2022) editions of the World HealthOrganization classification of myelodysplastic neoplasms.Leukemia 2022; 36: 2875-2882. https://doi.org/10.1038/s41375-022-01718-7.